Malaysian company Duopharma Biotech has reached an agreement with the country's government to supply the Russian vaccine against COVID, Sputnik V.
The statement on the company's website said Duopharma Biotech signed the vaccine document with the Malaysian Cabinet, represented by the country's Ministry of Health, and "finalized certain definitive agreements with the (Russian) government and the Russian Direct Investment Fund (RDIF) to supply... the Sputnik V vaccine."
Previously, the Malaysian authorities entered into a preliminary agreement with the US pharmaceutical company Pfizer to supply the COVID-19 vaccine. To date, Malaysia has also signed a contract to supply and partially produce the Sinovac vaccine in the country. Astrazeneca and Sinovac vaccines have also been approved for use in the country. The Director-General of the country's Ministry of Health, Noor Hisham Abdullah, previously reported that the National Pharmaceutical Regulatory Authority (NPRA) is evaluating and studying the Russian Sputnik V vaccine.
The Russian Sputnik V coronavirus vaccine has already been approved in 66 countries with a total population of over 3.2 billion people. Sputnik V has the second-highest number of approvals by state regulators in the world. The effectiveness of the vaccine was 97.6% based on analysis of data from 3.8 million vaccinated Russians, higher than the data previously published by The Lancet medical journal (91.6%), RFPI and Gamaleya Research Center previously reported.
GSV "Russia - Islamic World"
Photo: sputnikvaccine.com
Based on materials from RIA Novosti